Exelixis, Inc. (EXEL)
41.36
+0.29
(+0.71%)
USD |
NASDAQ |
Dec 11, 16:00
41.36
0.00 (0.00%)
After-Hours: 18:44
Exelixis Research and Development Expense (Quarterly): 199.16M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vanda Pharmaceuticals, Inc. | 22.56M |
| ADMA Biologics, Inc. | 1.528M |
| Aldeyra Therapeutics, Inc. | 5.431M |
| Merck & Co., Inc. | 3.552B |
| ACADIA Pharmaceuticals, Inc. | 87.83M |